US 11,929,171 B2
Methods for evaluation and treatment of glycemic dysregulation and atherosclerotic cardiovascular disease and applications thereof
Sophia Miryam Schüssler-Fiorenza Rose, Stanford, CA (US); Kevin Contrepois, Menlo Park, CA (US); Wenyu Zhou, Stanford, CA (US); Samson Mataraso, Stanford, CA (US); Tejaswini Mishra, Stanford, CA (US); Michael Snyder, Stanford, CA (US); Kegan Moneghetti, Stanford, CA (US); and Francois Haddad, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Oct. 18, 2019, as Appl. No. 16/657,878.
Claims priority of provisional application 62/845,161, filed on May 8, 2019.
Claims priority of provisional application 62/814,746, filed on Mar. 6, 2019.
Claims priority of provisional application 62/757,629, filed on Nov. 8, 2018.
Claims priority of provisional application 62/747,488, filed on Oct. 18, 2018.
Prior Publication US 2020/0227166 A1, Jul. 16, 2020
Int. Cl. G16H 50/20 (2018.01); G16B 5/00 (2019.01); G16H 10/40 (2018.01); G16H 10/60 (2018.01); G16H 20/10 (2018.01); G16H 50/70 (2018.01); G16H 70/60 (2018.01)
CPC G16H 50/20 (2018.01) [G16B 5/00 (2019.02); G16H 10/40 (2018.01); G16H 10/60 (2018.01); G16H 20/10 (2018.01); G16H 50/70 (2018.01); G16H 70/60 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A method to perform a treatment on an individual, comprising:
obtaining a panel of analyte measurements, wherein the analytes have been extracted from an individual;
entering the measurements of analytes as features in a computational predictive model to predict a steady-state plasma glucose level of the individual, wherein the computational predictive model has been trained utilizing data derived from a collection of individuals that have had their steady-state plasma glucose level clinically evaluated and their analytes extracted and measured;
receiving a diagnosis from the computational model that the individual has an elevated steady-state plasma glucose level; and
based on the received diagnosis that the individual has an elevated steady-state glucose level, treating the individual to lower the individual's elevated steady-state plasma glucose.